Brufsky A, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg L, Makari D, Candrilli S, Goyal R, Rugo H. Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: a SEER-Medicare analysis. Poster to be given at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2024. Chicago, IL.
Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli SD, Ajmera M. Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review. Clin Genitourin Cancer. 2023 Aug;21(4):459-66. doi: 10.1016/j.clgc.2023.03.011
Kaul S, Gosmanova EO, Castriota F, Hitchens A, Candrilli S, Parikh R, Esterberg E, Ayodele O. Recent trends in hypoparathyroidism-related inpatient and emergency department admissions and costs in the United States. J Endocr Soc. 2023 Apr 18;7(5):bvad050. doi: 10.1210/jendso/bvad050.
Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Corrigendum to: Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2020 Jan 13;7(1):ofz536. doi: 10.1093/ofid/ofz536
Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4
Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2019 Nov;6(11):ofz446. doi: 10.1093/ofid/ofz446